Helen Torley - PRESIDENT AND CEO, Director at HALOZYME THERAPEUTICS, INC.

Insider Transactions and Holdings

Entity Type
Individual
Role
PRESIDENT AND CEO, Director
Issuer Symbol
HALO on Nasdaq
All Insider Reports
All Insider Reports

Helen Torley - trading volume in the past year for HALOZYME THERAPEUTICS, INC.

Holdings reported by Helen Torley for HALOZYME THERAPEUTICS, INC.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 708,719 $55,943,442 $78.94 05 Feb 2026 Direct
Restricted Stock Units 67,308 $3,923,383 $58.29 23 Feb 2025 Direct Common Stock
Option to Purchase Common Stock 201,923 $2,437,210 $12.07 05 Feb 2026 Direct Common Stock
Performance Stock Unit 23,260 $1,311,980 $56.40 12 Feb 2025 Direct Common Stock
Performance Stock Units 165,522 $0 $56.40 09 Dec 2025 Direct Common Stock

Transactions reported by Helen Torley for HALOZYME THERAPEUTICS, INC.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.